A publicly-traded biotech company, International Stem Cell
Corporation (OTCQB: ISCO) focuses its efforts toward developing innovative
solutions that advance the field of regenerative medicine. This field strives
to create functional tissue to repair and replace tissue or organs that have
lost their function due to damage, disease, age, and congenital defects. ISCO
has contributed to regenerative science by developing its own novel stem cell
technology called parthenogenesis, which uses unfertilized eggs and addresses
immune-rejection among humans. Stem cells have the potential to divide and
differentiate themselves into any cell type. This means that these cells can
treat degenerative diseases of the eye, nervous system, and liver through
rebuilding and regeneration. Technological advancement in tissue engineering
and stem cell therapy is expected to drive the global market for regenerative
medicine.
Parthenogenesis uniquely studies immune-rejection, cell
differentiation, and DNA patterns. ISCO’s technology creates a whole new class
of stem cells called human parthenogenetic stem cells (hpSC). These are created
by stimulating the oocytes (unfertilized eggs) into dividing. Different oocyte
activation techniques create either heterozygous human parthenogenetic stem
cell lines or homozygous human parthenogenetic stem cell lines. The former
cells are only compatible with their donors, while the latter could be
compatible with a large portion of the population. To maximize this innovative
technology, the company developed the first collection of non-embryonic
histocompatible (human compatible) stem cells used for research or commercial
purposes. ISCO’s cell lines have the possibility of treating millions of people
around the world.
Immune-matching, histocompatible cells have the potential of
treating and even preventing diseases worldwide. For example, cancer is thought
to come from abnormal cell proliferation and differentiation. Using stem cells,
scientists can map out the human development of cells to see how cancer starts
while also discovering treatments and prevention. Other diseases like
Alzheimer’s and Parkinson’s could be treated using healthy cells to replace
damaged ones. This is an exciting time for stem cell research because of the
positive impact it could have around the globe.
To showcase increasing interest in their groundbreaking
developments, ISCO recently announced that negotiations between two healthcare
institutes and the company’s management have begun surrounding private
placement of $6.3 million of the company’s convertible preferred stock and common
stock purchase warrants to purchase $25.7 million of the company’s common
stock. With exposure and interest surrounding regenerative medicine steadily
increasing worldwide, ISCO is strongly poised to further its scientific studies
as successful contributors in the field.
For more information, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
